Table 1. Baseline characteristics of HIV-1 patients with or without AIDS progression in a Han Chinese population in Taiwan.
| Variable | Patients with AIDS progression | Patients with AIDS-non progression | |
| No. of participants | 90 | 53 | |
| Male sex, % | 91.1 | 90.6 | |
| Mean age at HIV-1 antibody positive (range), years a | 35.1 (21.3–56.1) | 36.0 (23.9–54.7) | |
| Total observation time since the person was examined HIV-1 sero-positive (range), days b | 2209.3 (1598–2961) | 2242.1 (1652–3109) | |
| Mean plasma HIV-1 viral load (range), log10 copies/mL c | 4.1 (2.6–5.8) | 3.6 (2.6–4.8) | |
| Mean CD4 count (range), cells/µL d | 379.0 (193–731) | 643.9 (411–1213) | |
| Mean CD8 count (range), cells/µL e | 1174.0 (379–2786) | 1332.50 (488–3717) | |
Statistical significance at p<0.05.
The age with HIV-1 antibody positive means the age of the person when he/she was examined with the earlist positive for HIV-1 antibody result. The HIV-1 antibody positive results were from the database of the department of medical and laboratory examination of our hospital.
p-value = 0.993 by using the unpaired Student t test. The total observation time is the duration between the lastest visiting date and the date when the person was examined with the earlist HIV-1 antibody positive result.
p-value <0.0001 by using the unpaired Student t test. The HIV-1 viral load was measured in peripheral blood sampled in the first 3–27 months when he/she was examined with the earlist HIV-1 antibody positive result. Any measurements taken after the start of anti-retroviral therapy were not used in any analysis.
p-value <0.0001 by using the unpaired Student t test. The CD4 count at enrollment was measured in peripheral blood sampled in the first 3–27 months when he/she was examined with the earlist HIV-1 antibody positive result. Any measurements taken after the start of anti-retroviral therapy were not used in any analysis.
p-value = 0.351 by using the unpaired Student t test. The CD8 count at enrollment was measured in peripheral blood sampled in the first 3–27 months when he/she was examined with the earlist HIV-1 antibody positive result. Any measurements taken after the start of anti-retroviral therapy were not used in any analysis.